UNCLASSIFIED

AD NUMBER

ADB232955

NEW LIMITATION CHANGE

TO

Approved for public release, distribution unlimited

FROM

Distribution authorized to U.S. Gov't. agencies only; Proprietary Information; Oct 97. Other requests shall be referred to US Army Medical Reserch and Materiel Comd., Fort Detrich, MD 21702-5012.

AUTHORITY

GRANT NUMBER DAMD17-96-1-6113

TITLE: Inducible Transgenic Models of BRCA1 Function

PRINCIPAL INVESTIGATOR: Lewis A. Chodosh, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of Pennsylvania
Philadelphia, Pennsylvania 19104-3246

REPORT DATE: October 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Oct 97). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Inducible Transgenic Models of BRCA1 Function

Chodosh, Lewis A., M.D., Ph.D.

University of Pennsylvania
Philadelphia, Pennsylvania 19104-3246

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Distribution authorized to U.S. Government agencies only (proprietary information, Oct 97). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

Germline mutations in the breast and ovarian cancer susceptibility gene, BRCA1, account for a large proportion of families with inherited breast and ovarian cancer. Interestingly, while germline BRCA1 mutations predispose carriers to adenocarcinoma of the breast, no somatic BRCA1 mutations have been found in sporadic primary breast cancers. This observation suggests that this molecule may normally protect the breast against carcinogenesis only during specific stages of mammary gland development. Previously, we have analyzed the temporal and spatial pattern of Brca1 expression during normal mouse embryogenesis, in adult tissues, and during postnatal mammary gland development. These studies support a role for Brca1 in the regulation of cell proliferation and differentiation in the breast during puberty and pregnancy. We hypothesize that Brca1 plays a critical role in mammary gland development, and that its function is temporally restricted to particular developmental phases. In this application, we propose to test this hypothesis by using a modified tetracycline-inducible expression system to either induce or abolish Brca1 expression in transgenic mice during particular developmental stages in a temporally-restricted and breast-specific manner. Through this approach, we hope to understand more clearly how the loss or mutation of this molecule contributes to carcinogenesis in a developmental-specific manner.
Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Signature Date
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Front Cover</td>
<td>1</td>
</tr>
<tr>
<td>Report Documentation Page</td>
<td>2</td>
</tr>
<tr>
<td>Foreword</td>
<td>3</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>4</td>
</tr>
<tr>
<td>Introduction</td>
<td>5</td>
</tr>
<tr>
<td>Body</td>
<td>7</td>
</tr>
<tr>
<td>Conclusions</td>
<td>13</td>
</tr>
<tr>
<td>References</td>
<td>14</td>
</tr>
</tbody>
</table>
INTRODUCTION

Genetic analysis of families in which multiple individuals have developed breast cancer suggests that 5-10% of breast cancer cases result from the inheritance of germline mutations in autosomal dominant susceptibility genes. Germline mutations in one of these breast cancer susceptibility genes, BRCA1, appear to account for most families with inherited breast and ovarian cancer, and somewhat less than half of families displaying inherited breast cancer alone. The BRCA1 gene encodes a 220 kDa phosphoprotein that contains a RING finger motif, a transcriptional activation domain, and a BRCT domain typically found in proteins involved in cell cycle regulation and DNA damage response. Tumors arising in patients with germline BRCA1 mutations almost invariably display loss of the wild-type BRCA1 allele, suggesting that BRCA1 is a tumor suppressor gene. Taken together with findings that reduction in BRCA1 expression in vitro results in accelerated growth of breast and ovarian cancer cell lines, and that overexpression of BRCA1 results in inhibited growth of such cell lines, these observations are consistent with a model in which BRCA1 negatively regulates proliferation in adult tissues. Interestingly, however, we have found that the murine homologue of BRCA1 is expressed at highest levels in the mouse in cellular compartments containing rapidly proliferating cells undergoing differentiation, such as are found in the breast during puberty and pregnancy. The positive correlation between Brca1 expression and cellular proliferation may be explained in part by the observation made in several laboratories, including our own, that the expression of this gene is regulated in a cell cycle-dependent manner with peak steady-state levels of mRNA and protein occurring just prior to and during S-phase. The discovery that BRCA1 is phosphorylated in a cell cycle-dependent fashion, as well as the finding that BRCA1 may be a substrate for certain cyclin-dependent kinases, suggests a possible function for BRCA1 in cell cycle progression and the regulation of proliferation. This hypothesis is supported by recent reports that BRCA1 overexpression inhibits cell cycle progression at least in part by upregulating expression of p21/WAF1/CIP1, a cyclin-dependent kinase inhibitor that contributes to the growth arrest response to DNA damage. Interestingly, recent studies have demonstrated that the BRCA1 protein forms a complex with Rad51. Since Rad51 is required for the proper response to ionizing radiation in yeast, these studies suggest a role for BRCA1 in the response to DNA damage. The observation that BRCA1 is rapidly phosphorylated in response to DNA damage, including that caused by ionizing radiation, strongly supports this model. It is important to note, however, that studies of tumor suppressor genes such as Rb and p53 and have highlighted the fact that proteins in this class typically function in multiple pathways and processes in the cell.

Interestingly, while germline BRCA1 mutations predispose carriers to adenocarcinoma of the breast, no somatic BRCA1 mutations have been found in sporadic primary breast cancers. This observation suggests that this molecule may normally protect the breast against carcinogenesis only during specific stages of mammary gland development. Previously, we have analyzed the temporal and spatial pattern of Brca1 expression during normal mouse embryogenesis, in adult tissues, and during postnatal mammary gland development. These studies support a role for Brca1 in the regulation of cell proliferation and differentiation in the breast during puberty and pregnancy. We hypothesize that Brca1 plays a critical role in mammary gland development, and that its function is temporally restricted to particular developmental phases. The focus of this project is to test this hypothesis by using a modified tetracycline-inducible expression system to either induce or abolish Brca1 expression in transgenic mice during particular developmental stages in a temporally-restricted and breast-specific manner. The goal of this work is therefore to understand more clearly how the loss or mutation of this molecule contributes to carcinogenesis in a developmental-specific manner. This goal will be accomplished by pursuing the following specific aims:

Specific Aim 1. Develop breast-specific, tetracycline-dependent expression systems to inducibly overexpress or abolish Brca1 expression in the mammary epithelium in vivo. We will develop a modified tetracycline-inducible expression system in order to conditionally express Brca1 or antisense Brca1 mRNA in the breast in a temporally-restricted manner. Constructs will be generated in which the
expression of the reverse tetracycline transcriptional activator, rtTA, will be breast-specific and dependent upon the presence of tetracycline. Since both the expression and function of rtTA are tetracycline-dependent, target expression constructs can be developed in which wild-type or mutant BRCA1 cDNA clones are expressed in a tetracycline-dependent manner by appending them to Tn10 operator-containing promoters. Additional target expression constructs will be developed in which Brca1 antisense RNA is expressed in a tetracycline-dependent manner. Transgenic mouse lines will be generated which overexpress the reverse tetracycline transcriptional activator, rtTA, in a breast-specific manner from the mouse mammary tumor virus LTR. Transgenic mouse lines will also be generated which overexpress the reverse tetracycline transcriptional activator, rtTA, in a tetracycline-dependent manner. Finally, transgenic mouse lines will be generated which contain target DNA constructs that direct the tetracycline-dependent expression of wild-type or mutant Brca1, or Brca1 antisense RNA. These transgenic strains should permit the inducible expression of target transgenes during specific stages of mammary gland development.

**Specific Aim 2. Inducibly overexpress Brca1 in the mammary epithelium of transgenic mice during specific developmental stages.** The effect of overexpressing Brca1 during specific stages of mammary gland development will be determined. Bitransgenic mice which express both the rtTA tetracycline-dependent transcriptional activator and a Brca1 wild-type or mutant transgene driven by a tetracycline-dependent promoter will be derived by mating each of the transgenic strains developed in specific aim 1. Brca1 overexpression in bitransgenic mice will be induced during specific stages of mammary gland development, including puberty, pregnancy, lactation and regression, by tetracycline treatment during the appropriate developmental window. Glands will be analyzed by morphological and molecular methods for abnormalities in mammary epithelial proliferation, differentiation and development, and for signs of hyperplasia, dysplasia and neoplasia.

**Specific Aim 3. Inducibly abolish Brca1 expression in the mammary epithelium of transgenic mice during specific developmental stages.** The effect of abolishing Brca1 expression during specific stages of mammary gland development will be determined by creating bitransgenic mice which express both the tetracycline-dependent transcriptional activator, rtTA, and a Brca1 antisense transgene driven by a tetracycline-dependent promoter by mating the transgenic strains developed in specific aim 1. Reduction of Brca1 expression in bitransgenic mice will be induced during specific stages of mammary gland development as above. Glands will be analyzed by morphological and molecular methods for abnormalities in mammary epithelial proliferation, differentiation and development, and for signs of hyperplasia, dysplasia and neoplasia.
BODY

Technical Objective I: Develop breast-specific, tetracycline-dependent expression systems to inducibly overexpress or abolish BRCA1 expression in mammary epithelial cells.

Task 1: Months 1-12: Construct vectors for expressing rtTA and/or tTA in the mammary epithelium.

In order to create an inducible expression system in mammary epithelial cells in vivo, we have constructed several mammary-specific and tetracycline-dependent expression vectors. Specifically, we have made use of the reverse tetracycline-controlled transcriptional activator, rtTA, that fuses the herpes simplex virus VP16 transcription activation domain with a mutant form of the DNA binding domain from the tet repressor of *E. coli*. This transactivator requires tetracycline derivatives for specific DNA binding. Target genes are placed under the control of the tetO regulatory cassette from the tetracycline-resistance operon of Tn10. This system has been documented to rapidly induce gene expression in the presence of tetracycline by up to three orders of magnitude with a low level of basal expression. Moreover, the availability of numerous tetracycline analogs with varied binding affinities, as well as the use of varying concentrations of tetracycline, permits the absolute level of transgene expression to be reproducibly and precisely titrated. As such, this system is ideally suited for the tight control and rapid induction of potentially toxic genes to desired levels of expression.

Plasmid pUHD172-1neo was constructed by Gossen et al. and contains a neomycin-selectable marker as well as sequences encoding the reverse tetracycline-controlled transcriptional activator, rtTA, whose expression is driven by a constitutive CMV promoter/enhancer. Plasmid pUHD15-1 was also constructed by Gossen et al. and contains a neomycin-selectable marker as well as sequences encoding the tetracycline-controlled transcriptional activator, tTA, whose expression is driven by a constitutive CMV promoter/enhancer.

Plasmid pMMTV.rtTA contains sequences encoding the reverse tetracycline-controlled transcriptional activator, rtTA, whose expression is driven by the mouse mammary tumor virus promoter/enhancer and was constructed by replacing the CMV promoter/enhancer of pUHD172-1neo with the entire MMTV promoter/enhancer long terminal repeat (LTR) containing 2.0 kb of upstream sequence. The MMTV LTR is widely used to obtain mammary-specific expression in transgenic mouse model systems.

Task 2: Months 1-12: Construct vectors for expressing rtTA and/or tTA in a tetracycline-dependent manner.

Since constitutive expression of rtTA has been reported to be detrimental in some cell types, we have created a modification of the tetracycline-dependent expression system by replacing the constitutive CMV-derived promoter/enhancer driving rtTA expression in pUHD172-1neo, with the tet regulatory sequences (tetO) from Tn10, to create the autoregulatory plasmid, pTetO.rtTA (Fig. 1A). A similar approach has been successfully taken by others with the original tTA tetracycline-repressible transcriptional activator. As a result, in this system the expression of the transcriptional activator, rtTA, is itself induced by the addition of tetracycline, and subsequently induces the target gene in a tetracycline-dependent manner. As a result, induction occurs at two different regulatory levels - the expression of the rtTA activator, and the binding and activation of the target promoter by rtTA.

Task 3: Months 1-12: Construct target vectors expressing wild type and mutant forms of BRCA1.

In order to permit the expression of target genes of interest in a tetracycline-dependent manner we have constructed a tetracycline-inducible expression vector, pTet-Target.Puro, that contains both a tetracycline-inducible promoter driving the expression of a target gene, and a puromycin-selectable marker (Fig. 1D). The puromycin-resistance gene, whose expression is driven by the PGK promoter, was obtained from the...
retroviral vector pLZRS as a ClaI-BspHI fragment, blunted with the Klenow fragment of DNA polymerase, and cloned in the NotI restriction site of pTet-Splice (Life Sciences).

In order to permit the inducible expression of wild-type BRCA1 in mammary epithelial cells in a tetracycline-dependent manner, a full-length cDNA encoding wild-type BRCA1 was subcloned into the HindIII site of pTet-Target.Puro to generate pTet.BRCA1.wt.

In order to permit the inducible expression of mutant forms of BRCA1 in mammary epithelial cells in a tetracycline-dependent manner, a cDNA clone encoding BRCA1 truncated at the carboxy-terminal Apal restriction site was subcloned into the HindIII site of pTet-Target.Puro to generate pTet.BRCA1.Apal. In addition, a cDNA clone encoding the naturally occurring mutant of BRCA1 C64G was constructed. This mutation contains a point mutation in the RING finger domain of BRCA1 that has been found to cosegregate with breast and ovarian cancer in BRCA1 families. This point mutation was created by PCR site-directed mutagenesis using overlapping PCR primers containing complementary mutational changes at C64. The resulting HindIII-BglII fragment containing the mutant region was subloned into wild-type BRCA1. The full-length HindIII fragment containing the mutant BRCA1 was then subcloned into the HindIII site of pTet-Target.Puro to generate pTet.BRCA1.C64G.

**Task 4: Months 1-12: Construct target vectors expressing BRCA1 antisense RNA.**

In order to permit the inducible expression of BRCA1 antisense RNA in mammary epithelial cells in a tetracycline-dependent manner, the target construct pTet.BRCA1.AS was generated. A 400 bp region containing the 5' region of mouse BRCA1 was amplified by RT-PCR from first-strand breast cDNA. This region spans the translation initiation codon of BRCA1. This 400 bp PCR fragment was sequenced on both strands to verify that it contained wild-type sequence and was then subcloned into the HindIII-EcoRV site of pTet-Target.Puro in the antisense orientation to generate pTet.BRCA1.AS. As a control, the same 400 bp fragment was subcloned into pTet-Target.Puro in the sense orientation to generate pTet.BRCA1.S.

In order to test the ability of the expression vectors described above to permit tetracycline-dependent inducible expression in mammary epithelial cells in vivo, we have used these constructs to generate a test inducible expression system in mammary epithelial cells in vitro. We have stably transfected pTetO.rtTA, which contains a neomycin-selectable marker, into HC11 mammary epithelial cells to generate the mammary epithelial cell clone, HC11.rtTA (Fig. 1A, B). This clone inducibly expresses the rtTA tetracycline-regulated transcriptional activator in the presence of tetracycline (Fig. 1B). In addition, we

---

**Fig. 1: Generation of a tetracycline-inducible expression system in mammary epithelial cells**

mammary epithelial cell clone, HC11.rtTA (Fig. 1A, B). This clone inducibly expresses the rtTA tetracycline-regulated transcriptional activator in the presence of tetracycline (Fig. 1B). In addition, we
have demonstrated that the HC11.rtTA clone faithfully differentiates in response to the lactogenic hormones, prolactin, insulin and hydrocortisone in the presence or absence of tetracycline, indicating that overexpression of rtTA does not interfere with the process of differentiation (Fig. 1C). This result suggests that the inducible expression of rtTA in mammary epithelial cells represents a suitable system for determining the effect of Brcal on mammary epithelial proliferation and differentiation.

In order to test the function of the tetracycline-inducible expression vector, pTet-Target.Puro, that contains both a tetracycline-inducible promoter driving the expression of a target gene, and a puromycin-selectable marker, pTetO-Target.Puro was stably transfected into HC11.rtTA (Fig. 1D). Puromycin-resistant clones obtained following transfection of HC11.rtTA cells with this construct express high levels of mRNA for the puromycin-resistance gene (Fig. 1E). No spontaneously puromycin-resistant clones have been detected following puromycin selection of untransfected HC11.rtTA cells.

In order to test the ability of the tetracycline-dependent transcriptional activator, rtTA, to induce the expression of the tetracycline-dependent target gene in the pTet-Target.Puro expression vector, the parental HC11.rtTA cell line has been stably transfected with pTet.BRCA1.AS. Puromycin-resistant clones were demonstrated to inducibly express Brcal antisense RNA in the presence of doxycycline (Fig. 2B). Induction occurs rapidly, is stable, and occurs in a graded fashion dependent on doxycycline concentration (Fig. 2C). Clones expressing antisense RNA are currently being assayed for their ability to specifically downregulate Brcal expression.

**Technical Objective II: Create transgenic mice overexpressing BRCA1 or BRCA1 antisense in the mammary epithelium.**

**Task 1: Months 8-24: Create and identify transgenic lines of mice expressing rtTA and/or tTA in the mammary epithelium.**

In order to test the hypothesis that Brcal plays a role in the normal control of mammary epithelial proliferation and differentiation in vivo, Brcal will be overexpressed in the mammary glands of transgenic mice. Given concerns regarding possible toxic effects of Brcal overexpression, we have chosen to conditionally overexpress Brcal in vivo using a tetracycline regulatory system. We have constructed a mammalian expression vector, pMMTV.rtTA, in which expression of the tetracycline-inducible transactivator, rtTA, is driven by the promoter/enhancer of the MMTV LTR. In order to generate transgenic mice harboring this construct, purified DNA containing the pMMTV-rtTA transgene was injected into fertilized oocytes harvested from superovulated FVB female mice. Two founder mice,
designated MTA and MTB, were identified that harbored the transgene in tail-derived DNA and that passed this transgene to offspring in a Mendelian fashion. Northern hybridization analysis of tissues derived from progeny of the MTA and MTB lines of mice revealed high levels of breast-specific rtTA expression in female virgin animals (Fig. 3). Expression was not detected in other tissues of female mice tested, and was expressed at markedly lower levels in the seminal vesicles of male mice, indicating that rtTA expression is breast-specific.

In order to create transgenic lines of mice that express rtTA in a tetracycline-dependent manner, purified DNA containing the pTetO,rtTA transgene was injected into fertilized oocytes harvested from superovulated FVB female mice. Two founder mice, designated TTB and TTE, were identified that harbored the transgene in tail-derived DNA and that passed this transgene to offspring in a Mendelian fashion. Northern hybridization analysis of tissues derived from progeny of the TTB and TTE lines of mice failed to reveal detectable levels of rtTA expression in the mammary glands of female virgin animals (Fig. 3). Low levels of expression of rtTA were detected in TTB and TTE animals in the thymus, kidney and spleen. The rtTA expression pattern of these animals is continuing to be characterized.

We have also constructed mammalian expression vectors, pTetO-LacZ, in which expression of the LacZ gene is driven by the tetO-containing promoter cassette, in order to serve as an indicator strain to permit the quantitative characterization of the rtTA/tetO-target bitransgenic expression system created in this proposal. This construct should permit the inducible expression of LacZ in response to tetracycline in cells expressing the rtTA transcriptional activator. Using an approach similar to that described above this construct, which also contains SV40 splicing and polyadenylation signals, has been used to generate transgenic mice in the FVB background. Founder animals have been identified that pass the pTetO-LacZ transgene to their offspring in a Mendelian fashion.

In order to determine whether this transgenic system will permit inducible transgene expression in the breast in response to tetracycline analogs, MMTV-rtTA transgenic mice were mated to TetO-LacZ mice and bitransgenic mice were identified. Wild-type (non-transgenic) and bitransgenic mice were treated with doxycycline. Breast tissue from wild-type and bitransgenic mice was harvested after 48 hours of treatment with doxycycline, as was breast tissue from a bitransgenic littermate that had not been treated with doxycycline. RNA was prepared from these three tissue samples and steady-state levels of rtTA and LacZ mRNA expression were assessed by Northern hybridization (Fig. 3B). As expected, bitransgenic animals expressed rtTA at similar levels in the presence and absence of doxycycline, whereas the LacZ

![Fig. 3: Bitransgenic system for inducibly overexpressing genes in the breast of transgenic mice](image-url)
target mRNA was only expressed in bitransgenic animals treated with doxycycline. No LacZ mRNA was detected either in wild-type animals, or in untreated bitransgenic animals.

In order to quantitate the level of lacZ protein expression in the induced and uninduced states, beta-galactosidase assays were performed on protein extracts made from each of the harvested breast tissues (Fig. 3C). As expected, no beta-galactosidase activity was detected in extracts prepared from non-transgenic breast tissue. Also as expected, abundant beta-galactosidase activity was present in extracts prepared from bitransgenic animals treated with doxycycline for 48 hours. Impressively, no beta-galactosidase activity was detected in protein extracts prepared from untreated bitransgenic animals. Based on the lower limits of detection for this assay, we estimate that the minimum induction of transgene expression observed in this experiment is at least 700-fold, and that the actual level of induction may be 1 or 2 logs higher. Our estimates of the minimum level of induction are comparable to that observed in a related system making use of the tTA tetracycline-dependent repressor, rather than the rtTA tetracycline-dependent transactivator. Our results suggest that the MMTV-rtTA/TetO-transgene system that we have generated will permit the rapid and breast-specific induction of transgene expression at high levels, in combination with extremely low levels of expression in the uninduced state. Notably, this system permits the modulation of transgene expression levels both by varying the concentration of doxycycline and by varying the tetracycline derivative used. These properties are ideal for determining the effects of a potentially toxic transgene on specific stages of mammary gland development, and for obtaining levels of transgene expression that are in the physiological range.

The TetO.rtTA transgenic lines of mice, TTB and TTE, will also be mated to TetO-LacZ mice in order to quantitate the pattern and extent of tetracycline inducibility of rtTA and of target genes in these bitransgenic animals.

**Task 2: Months 8-24:** Create and identify transgenic lines of mice expressing wild type and mutant forms of BRCA1 in a tetracycline-dependent manner.

As described above, we have constructed a mammalian expression vector, pTetO.BRCA1, in which expression of BRCA1 is driven by the tetO-containing promoter cassette. This construct should permit the inducible expression of BRCA1 in response to tetracycline in cells expressing the rtTA transcriptional activator. Using an approach similar to that described above this construct, which also contains SV40 splicing and polyadenylation signals, has been used to generate transgenic mice in the FVB background. To date, 1 founder animal has been identified that passes the pTetO-BRCA1 transgene to its offspring in a Mendelian fashion. This line of mice will be characterized as described below.

**Task 3: Months 8-24:** Create and identify transgenic lines of mice expressing BRCA1 antisense RNA in a tetracycline-dependent manner.

The completion of this task is pending at the current time. The antisense constructs described above will first be tested for their ability to specifically reduce the expression of BRCA1 protein using the HC11 in vitro test system that we have generated. If these experiments are successful, a DNA fragment containing the pTetO-BRCA1.AS expression cassette will be injected into fertilized oocytes harvested from superovulated FVB female mice, using an approach similar to that described above. Founder mice will be identified that harbor the transgene in tail-derived DNA and that pass this transgene to offspring in a Mendelian fashion.

**Task 4: Months 8-24:** Breed transgenic lines of mice to create a bitransgenic line of mice expressing wild type and mutant forms of BRCA1 in the breast in a tetracycline-dependent manner.
The completion of this task is pending at the current time. MMTV-rtTA transgenic mice identified above will be mated to offspring of the TetO-BRCA1 transgenic line described above. Bitransgenic offspring will be identified by PCR. The expression of BRCA1 will be induced in bitransgenic animals by treatment with doxycycline. Breast tissue will be harvested from treated and untreated bitransgenic animals as well as control non-transgenic animals. BRCA1 expression in the breast will be assayed at the mRNA level by Northern hybridization and RNase protection, and at the protein level by immunoblotting. Additional founder animals passing the pTetO-BRCA1 transgene to their offspring will also be characterized.

Task 5: Months 8-24: Breed transgenic lines of mice to create a bitransgenic line of mice expressing BRCA1 antisense in the breast in a tetracycline-dependent manner.

The completion of this task will depend on the successful completion of Task 3 in which transgenic lines of mice are created that express BRCA1 antisense RNA in a tetracycline-dependent manner.

Technical Objective III: Determine the effect of inducibly overexpressing BRCA1 in the mammary epithelium of transgenic mice during specific developmental stages.

Task 1: Months 24-48: Analyze the phenotype of inducibly overexpressing wild type BRCA1 in the mammary epithelium during specific developmental stages.

The completion of this task will depend on the successful completion of tasks described above in which bitransgenic lines of mice are generated that express wild type forms of BRCA1 in the breast in a tetracycline-dependent manner.

Task 2: Months 24-48: Analyze the phenotype of inducibly overexpressing mutant forms of BRCA1 in the mammary epithelium during specific developmental stages.

The completion of this task will depend on the successful completion of tasks described above in which bitransgenic lines of mice are generated that express mutant forms of BRCA1 in the breast in a tetracycline-dependent manner.

Technical Objective IV: Determine the effect of inducibly abolishing BRCA1 expression in the mammary epithelium of transgenic mice during specific developmental stages.

Task 1: Months 24-48: Analyze the phenotype of inducibly abolishing BRCA1 expression in the mammary epithelium during specific developmental stages.

The completion of this task will depend on the successful completion of tasks described above in which bitransgenic lines of mice are generated that express BRCA1 antisense RNA in the breast in a tetracycline-dependent manner and that result in the specific reduction in BRCA1 protein in mammary epithelial cells.
CONCLUSIONS

A number of important milestones have been accomplished during the first year of this project. We have constructed a variety of plasmid vectors for expressing rtTA in the mammary epithelium in a tetracycline-dependent or tetracycline-independent manner. We have also created target vectors for expressing wild-type and mutant forms of BRCA1, as well as target vectors for expressing BRCA1 antisense RNA. These vectors have been used to create four transgenic lines of mice containing the TetO-rtTA, MMTV-rtTA, TetO-LacZ and TetO-BRCA1 expression cassettes. Experiments to date demonstrate that the MMTV-rtTA transgenic line of mice express the tetracycline-dependent reverse transcriptional activator, rtTA, at high levels and in a breast-specific manner. The creation of bitransgenic MMTV-rtTA/TetO-LacZ mice has permitted the initial analysis of the utility of this inducible transgenic system. These results strongly suggest that this system is capable of inducing target gene expression to high levels in a breast-specific fashion in response to induction with tetracycline derivatives. In addition, this system demonstrates extremely low levels of basal expression.

The studies described above demonstrate that we have made significant progress towards the completion of the specific aims of this project during the first year. All technical objectives that were predicted to be complete by the end of the first year of this project have been successfully completed. In addition, substantial progress has also been made on a number of other technical objectives slated to be completed during the first two years of this project. These findings suggest that the experiments proposed can be executed in a timely fashion to answer important scientific questions regarding the function of the breast cancer susceptibility gene, BRCA1, in the mammary gland.
REFERENCES


MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports. Request the limited distribution statement for reports on the enclosed list be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Judy Pawlus at DSN 343-7322 or by e-mail at judy.pawlus@det.amedd.army.mil.

FOR THE COMMANDER:

[Signature]

PHYLIS M. RINEHART
Deputy Chief of Staff for Information Management